Potentiation of 2,5-hexanedione neurotoxicity by methyl ethyl ketone.
Chronic oral administration of a combination of 2.2 mmol methyl ethyl ketone (MEK) and 2.2 mmol 2,5-hexanedione (2,5-HD)/kg/day, 5 days/week resulted in more rapid onset of motor deficits than did chronic dosing with 2.2 mmol 2,5-HD/kg/day alone. In kinetic studies blood time courses of 2,5-HD were determined in rats in the presence and absence of MEK. Concomitant administration of MEK reduced blood 2,5-HD clearance and increased the area under the curve (AUC) for the blood 2,5-HD. In companion experiments with 2,5-[1,6-14C]HD as a tracer, neural and nonneural tissues were examined 72 hr following the last treatment at Weeks 1, 2, and 3 of chronic administration of 2,5-HD alone or in combination with an equimolar dose of MEK. Rats treated with 2,5-[14C]HD alone or in combination with MEK demonstrated no difference in total or trichloroacetic acid-precipitable radioactivity in blood, in liver homogenates, or in neurofilament-enriched fractions from sciatic nerve and spinal cord. The data support a suggestion that the potentiation of hexacarbon neurotoxicity by MEK is the result of the persistence of the neurotoxic metabolite in the blood and not the enhanced metabolism of parent hexacarbon to 2,5-HD.
D000284:Administration, Oral; D000818:Animals; D002074:Butanones / Q000494:pharmacology*; D002250:Carbon Radioisotopes; D004357:Drug Synergism; D006588:Hexanones / Q000097:blood / Q000633:toxicity*; D007659:Ketones / Q000633:toxicity*; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D051381:Rats; D011916:Rats, Inbred F344; D012018:Reflex / Q000187:drug effects
D002074:Butanones; D002250:Carbon Radioisotopes; D006588:Hexanones; D007659:Ketones; C005222:methylethyl ketone; C011269:2,5-hexanedione